JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Journal of Dermatology Research · 2024
DOI: 10.46889/jdr.2024.5101 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Dermatology Research, 2024. Verfasst von Fahad Ahmed und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Baricitinib, a JAK1/2 inhibitor, has been expanding its role as a therapeutic agent with recent FDA approval for dermatologic use with alopecia areata. Clinical trials are underway for further use of baricitinib for severe atopic dermatitis and multiple off-label uses in inflammatory dermatologic conditions such as lichen planus have been suggested. Few reports exist of patients with concomitant alopecia areata and lichen planus treated with baricitinib. We present a case of refractory oral lichen planus with marked improvement within one month following treatment with once daily baricitinib. Our case adds to the growing body of literature regarding the therapeutic benefits of JAK inhibitors in the treatment of lichen planus.
Zitieren
APA
Ahmed, F., Rahman, S. M., Memon, N., Rahman, N., & Haque, A. (2024). JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report. Journal of Dermatology Research. https://doi.org/10.46889/jdr.2024.5101
Vancouver
Ahmed F, Rahman SM, Memon N, Rahman N, Haque A. JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report. Journal of Dermatology Research. 2024. doi:10.46889/jdr.2024.5101
BibTeX
@article{Ahmed2024,
author = {Ahmed, Fahad and Rahman, Syed Minhaj and Memon, Nashwah and Rahman, Nishath and Haque, Adel},
title = {JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report},
journal = {Journal of Dermatology Research},
year = {2024},
doi = {10.46889/jdr.2024.5101}
}
EUVIMED